Browse AVPR2

Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.

> Gene Ontology
 
Biological Process GO:0001990 regulation of systemic arterial blood pressure by hormone
GO:0001992 regulation of systemic arterial blood pressure by vasopressin
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0003018 vascular process in circulatory system
GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal
GO:0003073 regulation of systemic arterial blood pressure
GO:0003084 positive regulation of systemic arterial blood pressure
GO:0003091 renal water homeostasis
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007190 activation of adenylate cyclase activity
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007588 excretion
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0019229 regulation of vasoconstriction
GO:0021537 telencephalon development
GO:0030104 water homeostasis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0030900 forebrain development
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0032609 interferon-gamma production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0035150 regulation of tube size
GO:0035809 regulation of urine volume
GO:0035811 negative regulation of urine volume
GO:0035812 renal sodium excretion
GO:0035813 regulation of renal sodium excretion
GO:0035814 negative regulation of renal sodium excretion
GO:0042310 vasoconstriction
GO:0044057 regulation of system process
GO:0044062 regulation of excretion
GO:0045761 regulation of adenylate cyclase activity
GO:0045762 positive regulation of adenylate cyclase activity
GO:0045777 positive regulation of blood pressure
GO:0045907 positive regulation of vasoconstriction
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0048871 multicellular organismal homeostasis
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0050886 endocrine process
GO:0050891 multicellular organismal water homeostasis
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055067 monovalent inorganic cation homeostasis
GO:0055078 sodium ion homeostasis
GO:0072522 purine-containing compound biosynthetic process
GO:0090066 regulation of anatomical structure size
GO:0098801 regulation of renal system process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901652 response to peptide
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0001653 peptide receptor activity
GO:0005000 vasopressin receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0033218 amide binding
GO:0042277 peptide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04962 Vasopressin-regulated water reabsorption
Reactome R-HSA-445717: Aquaporin-mediated transport
R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-5619099: Defective AVP causes neurohypophyseal diabetes insipidus (NDI)
R-HSA-1643685: Disease
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-199991: Membrane Trafficking
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-5619102: SLC transporter disorders
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
R-HSA-388479: Vasopressin-like receptors
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AVPR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AVPR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AVPR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1750.529
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2370.629
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1240.76
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8070.234
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0660.959
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.920.261
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1860.734
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0820.919
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3620.685
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0110.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7820.413
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3660.104
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AVPR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AVPR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AVPR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AVPR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AVPR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AVPR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAVPR2
Namearginine vasopressin receptor 2
Aliases V2R; nephrogenic diabetes insipidus; DIR3; DIR; DI1; NDI; AVPR V2; antidiuretic hormone receptor; renal-type ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AVPR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AVPR2.
ID Name Drug Type Targets #Targets
DB00035DesmopressinSmall MoleculeAVPR1A, AVPR1B, AVPR23
DB00067VasopressinSmall MoleculeAVPR1A, AVPR1B, AVPR23
DB00872ConivaptanSmall MoleculeAVPR1A, AVPR22
DB02638TerlipressinSmall MoleculeAVPR1A, AVPR1B, AVPR23
DB05091M0002Small MoleculeAVPR21
DB05838OPC-51803Small MoleculeAVPR21
DB06212TolvaptanSmall MoleculeAVPR1A, AVPR22